CLYM Earnings & Financial Statements
Climb Bio, Inc.
$10.84
+$0.55(+5.34%)
41
Overall
60
Value
27
Tech
36
Quality
Market Cap
$591.02M
Volume
182.41K
52W Range
$1.64 - $18.33
Target Price
$27.86
CLYM earnings and financial statements: Climb Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CLYM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $100.0K | $48.0K | - | - |
| Operating income | -$67.88M | -$82.02M | -$40.27M | -$45.13M | -$35.67M |
| EBITDA | -$59.75M | -$73.90M | -$35.12M | -$45.24M | -$47.23M |
| Net income | -$59.85M | -$73.90M | -$35.12M | -$45.24M | -$47.48M |
| EPS (diluted) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M |
| Total liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M |
| Shareholders’ equity | $160.47M | $211.88M | $107.60M | $128.72M | $167.20M |
| Cash and equivalents | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M |
| Long-term debt | $285.0K | $375.0K | $15.0K | $180.0K | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.36M | -$15.56M | -$20.60M | -$37.37M | -$36.07M |
| Capital expenditure | -$186.0K | -$4.64M | - | - | - |
| Free cash flow | -$54.54M | -$15.56M | -$20.60M | -$37.37M | -$36.07M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLYM | $10.84 | +5.3% | 182.41K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |